Standout Papers

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine 2017 2026 2020 2023 524
  1. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine (2018)
    David W. Dodick, Stephen D. Silberstein et al. JAMA
  2. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial (2019)
    Michel D. Ferrari, Hans‐Christoph Diener et al. The Lancet
  3. Fremanezumab for the Preventive Treatment of Chronic Migraine (2017)
    Stephen D. Silberstein, David W. Dodick et al. New England Journal of Medicine

Immediate Impact

5 from Science/Nature 55 standout
Sub-graph 1 of 20

Citing Papers

Nociceptive neurons promote gastric tumour progression via a CGRP–RAMP1 axis
2025 StandoutNature
Trigeminal ganglion neurons are directly activated by influx of CSF solutes in a migraine model
2024 StandoutScience
3 intermediate papers

Works of Ronghua Yang being referenced

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
2019 Standout
Fremanezumab for the Preventive Treatment of Chronic Migraine
2017 Standout

Author Peers

Author Last Decade Papers Cites
Ronghua Yang 1037 1436 177 920 124 3.5k
Yasemin Özdemir 1401 866 268 586 112 5.4k
Basil Sharrack 1114 578 180 2076 164 5.7k
Robert J. Morgan 1672 683 664 456 195 5.7k
Tomás Sobrino 1626 510 510 283 201 5.6k
Patrizio Sale 1043 649 80 249 103 4.0k
Charles A. Stewart 1344 479 124 740 102 6.0k
Kirk W. Johnson 2524 1518 177 942 131 7.4k
Haruhiko Kikuchi 1810 911 1194 384 256 8.1k
Yi Yang 1179 258 874 250 221 4.8k
Cristoforo Comi 1328 451 116 1866 203 5.8k

All Works

Loading papers...

Rankless by CCL
2026